NO20063080L - Azepinoindolderivater som farmasoytiske midler - Google Patents
Azepinoindolderivater som farmasoytiske midlerInfo
- Publication number
- NO20063080L NO20063080L NO20063080A NO20063080A NO20063080L NO 20063080 L NO20063080 L NO 20063080L NO 20063080 A NO20063080 A NO 20063080A NO 20063080 A NO20063080 A NO 20063080A NO 20063080 L NO20063080 L NO 20063080L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical agents
- modulating
- compounds
- azepinoindole derivatives
- methods
- Prior art date
Links
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- ISZIQZCZKOFSBT-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepine Chemical class N1=CC=CC=C2C3=NC=CC3=CC=C21 ISZIQZCZKOFSBT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100038495 Bile acid receptor Human genes 0.000 abstract 1
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 abstract 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000006255 nuclear receptors Human genes 0.000 abstract 1
- 108020004017 nuclear receptors Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Forbindelser for anvendelse i farmasøytiske sammensetninger og fremgangsmåter for å modulere aktiviteten til nukleære reseptorer, er tilveiebrakt. Særlig er forbindelser for anvendelse i sammensetninger og fremgangsmåter for a modulere farnesoid X-reseptoren og/eller orfannukleære reseptorer, tilveiebrakt: formel (I) eller et farmasøytisk akseptabelt derivat derav; hvori R1 er -C(J)OR14, -C(J)SR14 og -C(J)N(R15)R16; J er O, S eller NR17; R er hydrogen, halo eller eventuelt substituert alkyl; R3 er -C(O)R9; R4, R5, R6 og R7 er som beskrevet i kravene.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/895,431 US7595311B2 (en) | 2002-05-24 | 2003-12-02 | Azepinoindole derivatives as pharmaceutical agents |
| PCT/US2004/040352 WO2005056554A2 (en) | 2003-12-02 | 2004-12-01 | Azepinoindole derivatives as pharmaceutical agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063080L true NO20063080L (no) | 2006-08-23 |
Family
ID=34679499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063080A NO20063080L (no) | 2003-12-02 | 2006-07-03 | Azepinoindolderivater som farmasoytiske midler |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7595311B2 (no) |
| EP (1) | EP1692136A2 (no) |
| JP (2) | JP2007513168A (no) |
| KR (2) | KR20120091269A (no) |
| CN (2) | CN1914207A (no) |
| AU (1) | AU2004297198B2 (no) |
| BR (1) | BRPI0417260A (no) |
| CA (1) | CA2555279C (no) |
| CR (1) | CR8497A (no) |
| IL (1) | IL176014A0 (no) |
| NO (1) | NO20063080L (no) |
| NZ (1) | NZ548179A (no) |
| RU (1) | RU2423363C2 (no) |
| UA (1) | UA86957C2 (no) |
| WO (1) | WO2005056554A2 (no) |
| ZA (1) | ZA200604352B (no) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| JP4679517B2 (ja) * | 2003-07-23 | 2011-04-27 | エグゼリクシス, インコーポレイテッド | 薬剤としてのアゼピン誘導体 |
| US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| MXPA06010543A (es) | 2004-03-15 | 2007-03-26 | Ptc Therapeutics Inc | Derivados de carbolina utiles en la inhibicion de la angiogenesis. |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| DE102005016460A1 (de) * | 2005-04-11 | 2006-10-19 | Grünenthal GmbH | Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit |
| US7943576B2 (en) * | 2005-11-30 | 2011-05-17 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods of using enterostatin as inhibitor of angiogenesis |
| JP5420908B2 (ja) * | 2005-12-15 | 2014-02-19 | エグゼリクシス, インコーポレイテッド | 医薬的薬剤としてのアゼピノインドール誘導体 |
| AU2006329007A1 (en) * | 2005-12-20 | 2007-06-28 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutamate receptors |
| JP2010501567A (ja) * | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−CoA不飽和化酵素(SCD)阻害剤としての2−(ピラジン−2−イル)−チアゾールおよび2−(1H−ピラゾール−3−イル)チアゾール誘導体ならびに関連化合物 |
| KR20090053923A (ko) * | 2006-09-22 | 2009-05-28 | 노파르티스 아게 | 헤테로시클릭 유기 화합물 |
| CN101595105B (zh) * | 2006-12-20 | 2013-01-23 | 诺瓦提斯公司 | 作为scd抑制剂的2-取代的5元杂环化合物 |
| DE102007009235A1 (de) * | 2007-02-22 | 2008-09-18 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| US20080300235A1 (en) * | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
| US20080299118A1 (en) * | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for the Treatment of Malignancies |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20090163474A1 (en) * | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
| US20090215748A1 (en) * | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| US8716308B2 (en) | 2008-01-11 | 2014-05-06 | Albany Molecular Research, Inc. | (1-azinone)-substituted pyridoindoles |
| AU2009228647B2 (en) * | 2008-03-27 | 2013-07-04 | Grunenthal Gmbh | Substituted spirocyclic cyclohexane derivatives |
| ES2375543T3 (es) | 2008-03-27 | 2012-03-01 | Grünenthal GmbH | Derivados de espiro(5.5)undecano. |
| ES2464102T3 (es) | 2008-03-27 | 2014-05-30 | Grünenthal GmbH | Derivados de 4-aminociclohexano sustituidos |
| CN102046591B (zh) * | 2008-03-27 | 2014-12-03 | 格吕伦塔尔有限公司 | 羟甲基环己胺 |
| JP5529843B2 (ja) * | 2008-03-27 | 2014-06-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換シクロヘキシルジアミン |
| WO2010036362A1 (en) * | 2008-09-26 | 2010-04-01 | Wyeth | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
| CN105218565A (zh) | 2008-10-17 | 2016-01-06 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| TW201028414A (en) * | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| WO2011003012A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
| US8629158B2 (en) * | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| US8637501B2 (en) * | 2009-07-01 | 2014-01-28 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof |
| US9073925B2 (en) * | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| MX2012004373A (es) | 2009-10-14 | 2012-06-28 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol. |
| US20110103564A1 (en) * | 2009-10-30 | 2011-05-05 | Mitel Networks Corporation | System and method for communicating guest preferences to a telephony device |
| US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| US9193728B2 (en) | 2010-02-18 | 2015-11-24 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2011103487A1 (en) * | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2011103430A1 (en) * | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| CA2788440A1 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
| WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
| CN103476417A (zh) | 2011-02-18 | 2013-12-25 | 梅迪维新技术公司 | 治疗糖尿病的化合物和方法 |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| US20140155384A1 (en) | 2011-02-18 | 2014-06-05 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| HUE036985T2 (hu) | 2012-03-23 | 2018-08-28 | Codexis Inc | Biokatalizátor és eljárások triptamin és triptamin-analógok származékainak szintetizálására |
| US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
| BR112016002268B1 (pt) | 2013-08-01 | 2022-11-01 | The Penn State Research Foundation | Uso de inibidores do receptor x farnesoide |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| CA2968434A1 (en) * | 2014-11-21 | 2016-05-26 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| KR102000096B1 (ko) * | 2014-12-26 | 2019-07-15 | 후지필름 가부시키가이샤 | 농업 하우스용 필름 및 농업 하우스 |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| AU2016238523A1 (en) | 2015-03-26 | 2017-11-09 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| CN108271369A (zh) | 2015-10-23 | 2018-07-10 | 法尔玛赞公司 | 用于制备色胺及其衍生物的新工艺 |
| WO2017078928A1 (en) * | 2015-11-06 | 2017-05-11 | Salk Institute For Biological Studies | Fxr agonists and methods for making and using |
| WO2017143134A1 (en) * | 2016-02-19 | 2017-08-24 | Alios Biopharma, Inc. | Fxr modulators and methods of their use |
| MX385718B (es) | 2016-06-13 | 2025-03-18 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4). |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds |
| WO2018108231A1 (en) | 2016-12-12 | 2018-06-21 | Leo Pharma A/S | Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors |
| PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
| EP3911647B1 (en) | 2019-01-15 | 2023-12-13 | Gilead Sciences, Inc. | Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same |
| CA3233305A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| JP2024546484A (ja) * | 2021-12-10 | 2024-12-24 | ジーエーティーシー ヘルス コーポレーション | 中毒および神経障害を治療する方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445512A (de) * | 1964-12-03 | 1967-10-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen Indolderivaten |
| GR35044B (el) | 1966-05-10 | 1968-07-31 | The Upjohn Company | Μεθοδος παρασκευης οργανικων ενωσεων. |
| US3839357A (en) * | 1966-05-10 | 1974-10-01 | Upjohn Co | 1,2,3,4,5,6-hexahydroazepino(4,5-b)indoles |
| FR2455039A1 (fr) | 1979-04-26 | 1980-11-21 | Synthelabo | Pyrimido et imidazo-pyrido-indole-diones et leur application en therapeutique |
| US4362739A (en) | 1981-05-04 | 1982-12-07 | S.A. Omnichem | Pyrrolo(2,3-d)carbazole derivatives, compositions and use |
| LU85894A1 (fr) * | 1985-05-10 | 1986-12-05 | Omnichem Sa | Derives de 1,2,3,4,5,6-hexahydro-azepino (4,5-b) indole leur preparation,composes intermediaires,et leur application en therapeutique |
| HU198012B (en) | 1987-07-03 | 1989-07-28 | Richter Gedeon Vegyeszet | Process for producing cyclic amino-acid derivatives and pharmaceutical compositions containing them |
| ES2175404T3 (es) | 1996-05-10 | 2002-11-16 | Icos Corp | Derivados de carbolina. |
| HUP0302962A2 (hu) | 1998-06-12 | 2003-12-29 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Béta-karbolinszármazékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek alkalmazása |
| AU1025899A (en) | 1998-09-16 | 2000-04-03 | Icos Corporation | Carboline derivatives as cgmp phosphodiesterase inhibitors |
| US6544984B1 (en) * | 1999-01-27 | 2003-04-08 | American Cyanamid Company | 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids |
| US7030109B2 (en) | 1999-07-19 | 2006-04-18 | Pharmacia & Upjohn Company | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
| MY122278A (en) * | 1999-07-19 | 2006-04-29 | Upjohn Co | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
| FR2799757B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU2001292898A1 (en) * | 2000-09-20 | 2002-04-02 | Brad A. Acker | Substituted azepino[4,5b)indole derivatives |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| JP4679517B2 (ja) * | 2003-07-23 | 2011-04-27 | エグゼリクシス, インコーポレイテッド | 薬剤としてのアゼピン誘導体 |
-
2003
- 2003-12-02 US US10/895,431 patent/US7595311B2/en not_active Expired - Lifetime
-
2004
- 2004-12-01 NZ NZ548179A patent/NZ548179A/en not_active IP Right Cessation
- 2004-12-01 AU AU2004297198A patent/AU2004297198B2/en not_active Ceased
- 2004-12-01 BR BRPI0417260-4A patent/BRPI0417260A/pt not_active IP Right Cessation
- 2004-12-01 JP JP2006542742A patent/JP2007513168A/ja active Pending
- 2004-12-01 RU RU2006123424/04A patent/RU2423363C2/ru active
- 2004-12-01 CA CA2555279A patent/CA2555279C/en not_active Expired - Lifetime
- 2004-12-01 CN CNA200480041235XA patent/CN1914207A/zh active Pending
- 2004-12-01 CN CN2011102439838A patent/CN102358741A/zh active Pending
- 2004-12-01 UA UAA200607302A patent/UA86957C2/ru unknown
- 2004-12-01 EP EP04812795A patent/EP1692136A2/en not_active Withdrawn
- 2004-12-01 KR KR1020127014076A patent/KR20120091269A/ko not_active Abandoned
- 2004-12-01 WO PCT/US2004/040352 patent/WO2005056554A2/en not_active Ceased
-
2006
- 2006-05-29 ZA ZA200604352A patent/ZA200604352B/xx unknown
- 2006-05-30 IL IL176014A patent/IL176014A0/en unknown
- 2006-06-28 CR CR8497A patent/CR8497A/es not_active Application Discontinuation
- 2006-06-30 KR KR1020067013217A patent/KR101270072B1/ko not_active Expired - Lifetime
- 2006-07-03 NO NO20063080A patent/NO20063080L/no not_active Application Discontinuation
-
2009
- 2009-08-04 US US12/535,453 patent/US8524704B2/en not_active Expired - Fee Related
-
2011
- 2011-06-10 JP JP2011130688A patent/JP2011207907A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2423363C2 (ru) | 2011-07-10 |
| IL176014A0 (en) | 2006-10-05 |
| US8524704B2 (en) | 2013-09-03 |
| CN1914207A (zh) | 2007-02-14 |
| ZA200604352B (en) | 2008-12-31 |
| BRPI0417260A (pt) | 2007-03-06 |
| JP2011207907A (ja) | 2011-10-20 |
| UA86957C2 (ru) | 2009-06-10 |
| CR8497A (es) | 2006-11-17 |
| WO2005056554A2 (en) | 2005-06-23 |
| EP1692136A2 (en) | 2006-08-23 |
| CA2555279A1 (en) | 2005-06-23 |
| JP2007513168A (ja) | 2007-05-24 |
| RU2006123424A (ru) | 2008-01-10 |
| US20100173824A1 (en) | 2010-07-08 |
| AU2004297198B2 (en) | 2012-02-09 |
| US7595311B2 (en) | 2009-09-29 |
| WO2005056554A3 (en) | 2005-08-18 |
| US20050054634A1 (en) | 2005-03-10 |
| KR101270072B1 (ko) | 2013-05-31 |
| KR20120091269A (ko) | 2012-08-17 |
| KR20060124662A (ko) | 2006-12-05 |
| NZ548179A (en) | 2009-11-27 |
| CA2555279C (en) | 2012-10-23 |
| CN102358741A (zh) | 2012-02-22 |
| AU2004297198A1 (en) | 2005-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20063080L (no) | Azepinoindolderivater som farmasoytiske midler | |
| DE60208568D1 (de) | Prostaglandinanaloga als ep4-rezeptoragonisten | |
| NO20044826L (no) | Pyrrolidinderivater | |
| HRP20080052T3 (hr) | Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala | |
| DK1542997T3 (da) | Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| DE60335869D1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| NO20050164L (no) | Nye quinuklidin-amid-derivater | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| EP1679069A4 (en) | NEW PIPERIDINE DERIVATIVE | |
| NO20071922L (no) | Indazoler, benzisokazoler og benzinsotiazoler og anvendelse derav som ostrogene midler | |
| DK1697370T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| PE20080318A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| NO20055977L (no) | Nye benzimidazolderivater | |
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| NO970349D0 (no) | Forbindelser som er anvendbare som antiproliferative midler og GARFT inhibitorer | |
| NO20045486L (no) | Nye forbindelser og deres anvendelse | |
| NO20072409L (no) | Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser | |
| NO20070173L (no) | Nye forbindelser | |
| ATE374773T1 (de) | Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten | |
| NO20000722L (no) | 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater | |
| DE69401584D1 (de) | Beta,beta-dimethyl-4-piperidinethanamin-derivate als inhibitoren der cholesterin-biosynthese | |
| NO20070157L (no) | Substituerte diketopiperaziner som oksytocinantagonister | |
| HRP20080478T3 (hr) | Derivati 4-(2-fenilsulfanil-fenil)-piperidina kaoinhibitori ponovne pohrane serotonina | |
| NZ516100A (en) | Streptogramin derivatives, preparation and compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application | ||
| RE | Reestablishment of rights (par. 72 patents act) | ||
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |